好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Latent Class Analysis (LCA) of Treatment Preferences Among Adults with Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States
Autoimmune Neurology
P6 - Poster Session 6 (5:00 PM-6:00 PM)
1-012
To examine treatment preference heterogeneity among US adults with AQP4-Ab+ NMOSD by identifying segments of individuals with similar characteristics.

Prior findings from a survey of respondents with AQP4-Ab+ NMOSD showed that respondents prioritized reducing chance of relapse in the first year of treatment over other treatment attributes.
Data from a cross-sectional, web-based survey of US adults with AQP4-Ab+ NMOSD were used in a latent class model to identify patient segments with heterogeneous preferences.
Among 255 respondents, 3 segments with heterogeneous preferences were identified: relapse reducers (42.3%); benefit-risk balancers (33.8%); convenience seekers (23.9%). Relapse reducers placed greatest importance on reducing chance of relapse (60.0%) but lower importance on avoiding treatments with meningococcal infection risk (4.0%). Benefit-risk balancers prioritized both reducing chance of relapse (34.2%) and avoiding treatments with elevated liver enzyme risk (19.6%) but placed lower weight on administration frequency changes (11.8%). Convenience seekers prioritized treatments with less frequent dosing (18.3%) administered subcutaneously (13.4%). Relapse reducers had higher rituximab use (63.7% vs 42.9%/31.0%), were older (mean: 44.0yrs vs 40.4yrs/38.1yrs), and had the longest diagnosis time (mean: 7.1yrs vs 6.6yrs/5.8yrs) compared with benefit-risk balancers and convenience seekers. Benefit-risk balancers had more relapses in the past 12mo (mean: 10.0 vs 5.5/7.5) and the lowest proportion of respondents who were very/extremely satisfied with their treatment (45.2% vs 61.1%/46.6%) when compared with relapse reducers and convenience seekers. Convenience seekers had the longest travel time to treatment (mean: 56.6min vs 44.4min/41.1min) and the lowest rate of relapse-related hospitalizations (43.1% vs 66.4%/52.4%) compared with relapse reducers and benefit risk balancers.
In this survey of respondents with AQP4-Ab+ NMOSD, most were relapse reducers (42.3%) or benefit-risk balancers (33.8%) and prioritized reducing chance of relapse; convenience seekers (23.9%) prioritized mode/frequency of administration. These results show differences in treatment preferences among patient subgroups, which can inform patients’ treatment plan development.
Authors/Disclosures
Devon Conway, MD
PRESENTER 		Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Conway has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Conway has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Conway has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Conway has received research support from Novartis. The institution of Dr. Conway has received research support from BMS. The institution of Dr. Conway has received research support from Biogen.
Adrian Kielhorn Adrian Kielhorn has received personal compensation for serving as an employee of Alexion. Adrian Kielhorn has stock in Alexion.
Jeffrey Yu, PhD (Alexion) Dr. Yu has received personal compensation for serving as an employee of Alexion. Dr. Yu has stock in AstraZeneca.
Sami Fam Sami Fam has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Sami Fam has or had stock in Astra Zeneca.
Cannon R. Kent, MS Mr. Kent has received personal compensation for serving as an employee of RTI Health Solutions.
Kelley H. Myers, PhD Dr. Myers has nothing to disclose.
Christine Poulos, PhD Ms. Poulos has nothing to disclose.
Justin Abbatemarco, MD Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech . Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics, Inc.. Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. The institution of Dr. Abbatemarco has received research support from Amgen.